JOURNAL CLUB 

Artículos científicos comentados en formato de texto. El comentario incluirá los objetivos/preguntas principales del artículo, los métodos utilizados, los resultados obtenidos y las conclusiones del estudio. El comentario explicará específicamente la validez de los métodos y contextualizará los resultados y sus posibles implicaciones.

• PURPOSE-1 and PURPOSE-2 studies on the efficacy of lenacapavir (LEN) in HIV pre-exposure prophylaxis (PrEP). Linda-Gail Bekker, Moupali Das, Colleen F.Kelley, Maribel Acevedo-Quiñones. NEJM. December 2024.
• Comentado por Sergio Padilla

• 48-week viral suppression rates in people with HIV starting long-acting CAB/RPV with initial viremia. Hickey MD, Gistand N, Grochowski J et al. Clinical Infectious Diseases, November 2024.
• Comentado por Javier García

• Implementation of long-acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations Cassidy A. Gutner, Laurent Hocqueloux . J Int AIDS,  November 2024.
• Comentado por Miguel García.

• Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure Prophylaxis. Raphael J. Landovitz.  NEJM, October 2024.

• Comentado por Enrique Bernal.

• Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.Cissy Kityo, Ivan K Mambule.  The Lancet, June 2024.
• Comentado por Pere Domingo.

• Case Series of People With HIV on the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial.Gandhi M, Hill L. Clinical Infectious Diseases,  June 2024 .
• Comentado por Vicente Estrada.

• Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study. Joseph J Eron. Susan J Little.  Lancet HIV, May 2024.
• Comentado por Federico García.

• Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland. Paul Thoueillea, Susana Alves Saldanhaa, Fabian Schaller et al. The Lancet, April 2024.
• Comentado por Miguel Górgolas.

• Effect of obesity on the exposure of long-acting cabotegravir and rilpivirine: a modelling study. Sara Bettonte, Mattia Berton, Felix Stader et al. Clinical Infectious Diseases, March  2024.
• Comentado por Mar Masiá. 

• Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis. Berend J van Welzen, Steven F L Van Lelyveld, Gerjanne Ter Beest et al. Clinical Infectious Diseases, March 2024.
• Comentado por Félix Gutiérrez.